Entasis Therapeutics Holdings Inc.
ETTX
ETTX was delisted on the 8th of July, 2022.
19 hedge funds and large institutions have $95.2M invested in Entasis Therapeutics Holdings Inc. in 2018 Q3 according to their latest regulatory filings, with 19 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
NHAS
Novo Holdings A/S
Hellerup,
Denmark
|
+$22.9M |
| 2 |
CV
Clarus Ventures
Cambridge,
Massachusetts
|
+$17.1M |
| 3 |
FM
Frazier Management
Seattle,
Washington
|
+$14.2M |
| 4 |
SI
Sofinnova Investments
Menlo Park,
California
|
+$12.4M |
| 5 |
TGHSA
TPG Group Holdings (SBS) Advisors
Fort Worth,
Texas
|
+$10.7M |
Top Sellers
ETTX Hedge Fund Activity: Q3 2018 in Review
19 of the 4,391 institutional investors tracked by Wall St. Rank reported a position in Entasis Therapeutics Holdings Inc. (ETTX) for Q3 2018, worth a combined $95.2M.
Buyers outnumbered sellers: 19 funds opened new ETTX positions and 0 closed out — a net gain of 19 holders — while 0 added to existing stakes and 0 trimmed.
The largest buyer was Novo Holdings A/S, opening a new position worth an estimated $22.9M.
- 19 institutional investors held Entasis Therapeutics Holdings Inc. (ETTX) as of Q3 2018, up from 0 in Q2 2018.
- Funds reported $95.2M of Entasis Therapeutics Holdings Inc. stock for Q3 2018.
- 19 funds opened new Entasis Therapeutics Holdings Inc. positions in Q3 2018 and 0 closed out, a net change of +19 holders.
- The largest Entasis Therapeutics Holdings Inc. buyer in Q3 2018 was Novo Holdings A/S, an estimated $22.9M added.
Based on aggregated 13F filings for Q3 2018.